Biolegend, 109829, PE/Cyanine7 anti-mouse CD45.2 Antibody, 25μg

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: B10.S mouse thymocytes and splenocytes
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, in vivo and in vitro blocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3.
Application References(PubMed link indicates BioLegend citation): Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block) Yakura H, et al. 1986. J. Immunol. 136:2729. (Block) Suzuki K, et al. 2000. Immunity 13:691. (IHC) Shen FW, et al. 1986. Immunogenetics 24:146. (IP) Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837. Pascal V, et al. 2007. J. Immunol. 179:1751. Burman AC, et al. 2007. Blood 110:1064. Kincaid EZ, et al. 2007. J. Immunol. 179:3187. Phan TG, et al. 2007. Nature Immunol. 8:992. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed Wen T, et al. 2013. PNAS. 110:6067. PubMed Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations: Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed Wang YC, et al. 2023. J Exp Med. 220:. PubMed Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed He D, et al. 2022. Immunity. 55:159. PubMed Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed Simpson AP, et al. 2022. Cell Rep. 40:111099. PubMed Frederico B, et al. 2022. Dev Cell. 57:1957. PubMed Zhao M, et al. 2022. Nat Commun. 13:7600. PubMed Giannou AD, et al. 2023. Immunity. 56:125. PubMed Oh S, et al. 2023. Nat Biotechnol. :. PubMed Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed Boyd DF, et al. 2020. Nature. 587:466. PubMed Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed Mylonas K, et al. 2015. Immunobiology. 220: 924-933. PubMed Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed Roeschert I, et al. 2021. Nat Cancer. 2:312. PubMed Kumaraswami K, et al. 2020. Int J Mol Sci. 21:00. PubMed Gruber T, et al. 2020. JCI Insight. 5:00. PubMed Li H, Watowich S 2014. J Vis Exp. 85: 51189. PubMed Schwartz DM et al. 2019. Immunity. 50(1):106-120 . PubMed Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed Casali P, et al. 2021. Front Immunol. 12:761450. PubMed Blijswijk J, et al. 2015. J Immunol. 194:307. PubMed LaMothe RA et al. 2018. Front Immunol. 0.570138889 . PubMed Tang Y, et al. 2015. Exp Hematol. 43: 554-564. PubMed Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed Salei N, et al. 2020. J Am Soc Nephrol. 31:257. PubMed JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed Kim P, et al. 2015. J Exp Med. 212:633. PubMed Kaplan BLF et al. 2018. Current protocols in toxicology. 75:11:00 25. PubMed Sundling C, et al. 2021. Immunity. 54(5):988-1001.e5. PubMed Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed Progatzky F, et al. 2021. Nature. 599:125. PubMed Cohen SB et al. 2018. Cell host & microbe. 24(3):439-446 . PubMed Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed Steinbicker A, et al. 2011. Blood. 117:4915. PubMed Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed Bastow CR, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Beura LK, et al. 2018. Immunity. 48:327. PubMed Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed Tuong ZK, et al. 2021. iScience. 24:103326. PubMed Nuro-Gyina PK, et al. 2021. J Immunol. 207:868. PubMed Anderson-Baucum E, et al. 2021. Cell Metab. 33:1883. PubMed Ulland T, et al. 2016. Nat Commun. 7:13180. PubMed Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed Sheng J, et al. 2021. eLife. 10:00. PubMed Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed Luo H, et al. 2019. Cell Rep. 26:945. PubMed Zhang B, et al. 2021. Nature. 599:471. PubMed Spath S, et al. 2022. iScience. 25:104998. PubMed Koronyo Y, et al. 2015. Brain. 138: 2399-2422. PubMed Puleston D, et al. 2014. Elife. 3:3706. PubMed Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed Chen S, et al. 2018. Nat Commun. 9:5298. PubMed Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed Deets KA, et al. 2021. Elife. 10:. PubMed Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
RRID: AB_1186103 (BioLegend Cat. No. 109829) AB_1186098 (BioLegend Cat. No. 109830)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules
Antigen References: 1. Suzuki K, et al. 2000. Immunity 13:691.
Gene ID: 19264
UniProt: View information about CD45.2 on UniProt.org
Clone: 104
Regulatory Status: RUO
Other Names: Ly-5.2, LCA
Isotype: Mouse (SJL) IgG2a, κ